Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Transpl Infect Dis. 2019 Dec 30;22(2):e13233. doi: 10.1111/tid.13233

Table 3:

Adverse Effects Leading to Therapy Adjustment

Ganciclovir (n=52) Foscarnet (n=12) P Value
Filgrastim Use
 # of Patients (%) 28 (54%) 9 (75%) 0.21
 Median # of Doses (Range) 1 (0 to 23) 4 (0 to 25) 0.27
Dialysis
 # of Patients (%) 0 (0%) 3 (25%) <0.05
 Median # of Days (Range) - 36 (1 to 79) -
 Total # of Days - 116 -
 # of Days per Patient - 9.7 -